A Phase II Randomized, Control, Multi-center Study of Recombinant Humanized Anti-PD-1 mAb for Injection Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery
Latest Information Update: 05 Aug 2022
At a glance
- Drugs Toripalimab (Primary) ; Interferon alpha-2b
- Indications Malignant melanoma; Mucosal disorders
- Focus Therapeutic Use
- Sponsors Shanghai Junshi Biosciences
- 13 Jul 2022 Results published in the Annals of Oncology
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 28 Sep 2020 Status changed from recruiting to active, no longer recruiting.